Close
Anne–Marie Langevin, MD
NOTE : If you're an existing patient, please connect via MyChart
-
About Me
About Anne–Marie Langevin, MD
Gender
- Female
Languages Spoken
- French
- Spanish
- Urdu
-
Credentials
Credentials
Certifications
- American Board of Pediatrics/Hematology-Oncology
Education
- Medical School: University of Montreal
- Internship: Hôpital Maisonneuve-Rosemont, Montreal, Canada
- Residency:
- Hospital Maisonneuve Rosemont
- Hotel Dieu de Montreal Hospital Ste Justine
- Fellowship:
- Hospital for Sick Children
- University of North Carolina Hospital
- Locations & Contact
-
Research & Publications
Research & Publications
Zoledronic acid therapy for recurrent giant cell tumor of the C2 vertebra in an adolescent.
Bartanusz, V., Ziu, M., Jimenez, D. F., Crownover, R. L. & Langevin, A. M.
Spine J. 1;15(8):1886-7 (2015). PMID: 25817726
Hemophagocytic lymphohistiocytosis in Texas: observations on ethnicity and race.
Niece, J.A., Rogers, Z.R., Ahmad, N., Langevin, A.M. & McClain, K.L.
Pediatr Blood Cancer 54(3):424-8 (2010). PMID:19953651
Characterization of Localized Osteosarcoma of the Extremity in Children, Adolescents, and Young Adults From a Single Institution in South Texas.
Sugalski, A. J., Jiwani, A., Ketchum, N. S., Cornell, J., Williams, R., Heim-Hall, J., Hung, J. Y. & Langevin, A. M.
J. Pediatr. Hematol. Oncol. 36(6):e353-8 (2014). PMID: 24487915; PMCID: PMC4222611
-
Clinical Trials
Clinical Trials
Type of Cancer
Multiple Sites
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Anne–Marie Langevin MD
DCP-001, Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
A clinical trial screening tool protocol has been developed to facilitate the formulation of research questions; particularly those evaluating factors related to populations that are underrepresented in clinical trials, and address cancer care disparities. This protocol is designed to allow the collection, storage and abstraction of clinical and demographic data obtained during the screening…
Type of Cancer
Multiple Sites
ClinicalTrials.gov Identifier
NCT02717507
Principal Investigator
Anne–Marie Langevin MD
ALTE1621, Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial
This phase IIb trial studies how well low-dose carvedilol works in preventing heart failure in cancer survivors exposed to high dose anthracyclines for management of childhood cancer. Patients who received high-dose anthracycline chemotherapy are at a much greater risk for developing heart failure compared to survivors who didn't get any anthracycline chemotherapy. Heart failure happens when the…
Type of Cancer
Multiple Sites
ClinicalTrials.gov Identifier
NCT02932280
Principal Investigator
Anne–Marie Langevin MD
POE16-01, A Phase I/II Study of Neratinib in Pediatric Patients with Relapsed/Refractory Solid Tumors or Hematologic Malignancies
The purpose of this study is to test the safety of neratinib at different dose levels and to find out what effects, good and bad, it has on the patients and the cancer.
Type of Cancer
Multiple Sites
ClinicalTrials.gov Identifier
NCT03067181
Principal Investigator
Anne–Marie Langevin MD
AGCT1531, A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
This phase III trial studies how well active surveillance, bleomycin, carboplatin, etoposide, or cisplatin work in treating pediatric and adult patients with germ cell tumors. Active surveillance may help doctors to monitor subjects with low risk germ cell tumors after their tumor is removed. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different…
Type of Cancer
Brain & Nervous System
ClinicalTrials.gov Identifier
NCT02724579
Principal Investigator
Anne–Marie Langevin MD
ACNS1422, A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
This phase II trial studies how well reduced doses of radiation therapy to the brain and spine (craniospinal) and chemotherapy work in treating patients with newly diagnosed type of brain tumor called WNT)/Wingless (WNT)-driven medulloblastoma. Recent studies using chemotherapy and radiation therapy have been shown to be effective in treating patients with WNT-driven medulloblastoma. However,…
Type of Cancer
Multiple Sites
ClinicalTrials.gov Identifier
NCT03213704
Principal Investigator
Anne–Marie Langevin MD
APEC1621A, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 sub-protocol of LOXO-101 (larotrectinib) in patients with tumors harboring NTRK fusions.
This phase II Pediatric MATCH trial studies how well larotrectinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with NTRK fusions that have spread to other places in the body and have come back or do not respond to treatment. Larotrectinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Type of Cancer
Multiple Sites, Non-Hodgkin's Lymphoma
ClinicalTrials.gov Identifier
NCT03155620
Principal Investigator
Anne–Marie Langevin MD
APEC1621C, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Tazemetostat in Patients with Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic…
Type of Cancer
Multiple Sites, Non-Hodgkin's Lymphoma
ClinicalTrials.gov Identifier
NCT03213691
Principal Investigator
Anne–Marie Langevin MD
APEC1621E, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) MATCH - Phase 2 Subprotocol of Selumetinib (AZD6244 hydrogen sulfate) in patients with tumors harboring activating MAPK pathway mutations
This phase II Pediatric MATCH trial studies how well selumetinib sulfate works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with MAPK pathway activation mutations that have spread to other places in the body and have come back or do not respond to treatment. Selumetinib sulfate may stop the growth of cancer cells by blocking some of the enzymes needed for…
Type of Cancer
Multiple Sites
ClinicalTrials.gov Identifier
NCT03213652
Principal Investigator
Anne–Marie Langevin MD
APEC1621F, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of Ensartinib in patients with tumors harboring ALK or ROS1 genomic alterations
This phase II Pediatric MATCH trial studies how well ensartinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with ALK or ROS1 genomic alterations that have come back (recurrent) or do not respond to treatment (refractory) and have spread to other places in the body (advanced). Ensartinib may stop the growth of tumor cells by blocking some of the…
Type of Cancer
Multiple Sites
ClinicalTrials.gov Identifier
NCT03155620
Principal Investigator
Anne–Marie Langevin MD
APEC1621G, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Vemurafenib in patients with tumors harboring BRAF V600 mutations
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic…
Type of Cancer
Multiple Sites
ClinicalTrials.gov Identifier
NCT03155620
Principal Investigator
Anne–Marie Langevin MD
APEC1621H, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of olaparib in patients with tumors harboring defects in DNA damage repair genes
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic…
Type of Cancer
Multiple Sites
ClinicalTrials.gov Identifier
NCT03210714
Principal Investigator
Anne–Marie Langevin MD
APEC1621B, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of JNJ-42756493 (Erdafitinib) in patients with relapsed pediatric solid tumors harboring FGFR1/2/3/4 alteration
This phase II Pediatric MATCH trial studies how well erdafitinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have spread to other places in the body and have come back or do not respond to treatment with FGFR mutations. Erdafitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Type of Cancer
Multiple Sites
ClinicalTrials.gov Identifier
NCT03533582
Principal Investigator
Anne–Marie Langevin MD
AHEP1531 Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT); A Phase 2/3 StudyCTMS#: 18-0100
This partially randomized phase II/III trial studies how well, in combination with surgery, cisplatin and combination chemotherapy works in treating children and young adults with hepatoblastoma or hepatocellular carcinoma. Drugs used in chemotherapy, such as cisplatin, doxorubicin, fluorouracil, vincristine sulfate, carboplatin, etoposide, irinotecan, sorafenib, gemcitabine and oxaliplatin, work…
Type of Cancer
Multiple Sites
ClinicalTrials.gov Identifier
NCT03526250
Principal Investigator
Anne–Marie Langevin MD
APEC1621I (CTMS 18-0149); NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes (CTMS# 18-0149)
This phase II Pediatric MATCH trial studies how well palbociclib works in treating patients with Rb positive solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with activating alterations (mutations) in cell cycle genes that have spread to other places in the body and have come back or do not respond to treatment. Palbociclib may stop the growth of cancer cells by blocking some of the…
Type of Cancer
Multiple Sites, Non-Hodgkin's Lymphoma
ClinicalTrials.gov Identifier
NCT03698994
Principal Investigator
Anne–Marie Langevin MD
APEC1621J (CTMS 18-0148); NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations (CTMS# 18-0148)
This phase II Pediatric MATCH trial studies how well ulixertinib works in treating patients with solid tumors that have spread to other places in the body (advanced), non-Hodgkin lymphoma, or histiocytic disorders that have a genetic alteration (mutation) in a signaling pathway called MAPK. A signaling pathway consists of a group of molecules in a cell that control one or more cell functions…
ClinicalTrials.gov Identifier
NCT02180867
Principal Investigator
Anne–Marie Langevin MD
ARST1321, Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613
This randomized phase II/III trial studies how well pazopanib, when combined with chemotherapy and radiation therapy or radiation therapy alone, work in the treatment of patients with newly diagnosed non-rhabdomyosarcoma soft tissue sarcomas that can eventually be removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as ifosfamide and…
ClinicalTrials.gov Identifier
NCT01096368
Principal Investigator
Anne–Marie Langevin MD
ACNS0831, Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years
This partially randomized phase III trial is studying maintenance chemotherapy to see how well it works compared to observation following induction chemotherapy and radiation therapy in treating young patients with newly diagnosed ependymoma. Drugs used in chemotherapy, such as vincristine sulfate, carboplatin, cyclophosphamide, etoposide, and cisplatin, work in different ways to stop the growth…
Type of Cancer
Acute Lymphoblasic Leukemia
ClinicalTrials.gov Identifier
NCT02883049
Principal Investigator
Anne–Marie Langevin MD
AALL1131, A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
This randomized phase III trial studies how well combination chemotherapy works in treating young patients with newly diagnosed B acute lymphoblastic leukemia that is likely to come back or spread, and in patients with Philadelphia chromosome (Ph)-like tyrosine kinase inhibitor (TKI) sensitive mutations. Chemotherapy drugs, work in different ways to stop the growth of cancer cells, either by…
ClinicalTrials.gov Identifier
NCT01142427
Principal Investigator
Anne–Marie Langevin MD
AALL08B1 Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
This research trial studies a risk-based classification system for patients with newly diagnosed acute lymphoblastic leukemia. Gathering health information about patients with acute lymphoblastic leukemia may help doctors learn more about the disease and plan the best treatment.
ClinicalTrials.gov Identifier
NCT01190930
Principal Investigator
Anne–Marie Langevin MD
AALL0932, Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)
This partially randomized phase III trial studies the side effects of different combinations of risk-adapted chemotherapy regimens and how well they work in treating younger patients with newly diagnosed standard-risk acute lymphoblastic leukemia or B-lineage lymphoblastic lymphoma that is found only in the tissue or organ where it began (localized). Drugs used in chemotherapy work in different…
ClinicalTrials.gov Identifier
NCT00352534
Principal Investigator
Anne–Marie Langevin MD
COG AREN0532: Treatment for Very Low, Low and Standard Risk Favorable Histology Wilms Tumor. A Groupwide Phase III Study
This phase III trial is studying vincristine, dactinomycin, and doxorubicin with or without radiation therapy or observation only to see how well they work in treating patients undergoing surgery for newly diagnosed stage I, stage II, or stage III Wilms' tumor. Drugs used in chemotherapy, such as vincristine, dactinomycin, and doxorubicin, work in different ways to stop the growth of tumor cells,…
ClinicalTrials.gov Identifier
NCT00408005
Principal Investigator
Anne–Marie Langevin MD
AALL0434 Intensified Methotrexate, Nelarabine (Compound 506U78; IND#52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma
This randomized phase III trial is studying different combination chemotherapy regimens and their side effects and comparing how well they work in treating young patients with newly diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them…
ClinicalTrials.gov Identifier
NCT00379340
Principal Investigator
Anne–Marie Langevin MD
AREN0533. Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors. A Groupwide Phase III Study
This phase III trial is studying how well combination chemotherapy with or without radiation therapy works in treating young patients with newly diagnosed stage III or stage IV Favorable Histology Wilms' tumor. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x…
ClinicalTrials.gov Identifier
NCT01117168
Principal Investigator
Anne–Marie Langevin MD
ACCRN07, Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN)
Background: - The Children s Oncology Group has established a research network, the Childhood Cancer Research Network (CCRN), to collect information about children with cancer and other conditions that are benign but involve abnormal cell growth in order to help doctors and scientists better understand childhood cancer. The CCRN's goal is to collect clinical information about every child…
ClinicalTrials.gov Identifier
NCT00653068
Principal Investigator
Anne–Marie Langevin MD
ACNS0333: Treatment of Atypical Teratoid/Rhabdoid Tumors (AT/RT) of the Central Nervous System with Surgery, Intensive Chemotherapy, and 3-D Conformal Radiation.
This phase III trial studies the side effects of combination chemotherapy, 3-dimensional conformal radiation therapy, and an autologous peripheral blood stem cell transplant, and to see how well they work in treating young patients with atypical teratoid/rhabdoid tumor of the central nervous system. Giving high-dose chemotherapy before an autologous peripheral blood stem cell transplant stops the…
ClinicalTrials.gov Identifier
NCT00945009
Principal Investigator
Anne–Marie Langevin MD
AREN0534, Treatment for Patients with Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor
This phase III trial studies how well combination chemotherapy and surgery work in treating young patients with Wilms tumor. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving…
ClinicalTrials.gov Identifier
NCT01798004
Principal Investigator
Anne–Marie Langevin MD
ANBL12P1, Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma
This pilot clinical trial studies busulfan, melphalan, and stem cell transplant after chemotherapy in treating patients with newly diagnosed neuroblastoma that is likely to come back or spread. Giving chemotherapy to the entire body before a stem cell transplant stops the growth of tumor cells by stopping them from dividing or killing them. After treatment, stem cells are collected from the…
Type of Cancer
Acute Lymphoblasic Leukemia
ClinicalTrials.gov Identifier
NCT02981628
Principal Investigator
Anne–Marie Langevin MD
AALL1621: A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL) CTMS#: 18-0156
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive…
Type of Cancer
Oligodendroglial Tumors
ClinicalTrials.gov Identifier
NCT03581292
Principal Investigator
Anne–Marie Langevin MD
ACNS1721: A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations (CTMS# 18-0153)
This phase II trial studies how well veliparib, radiation therapy, and temozolomide work in treating patients with newly diagnosed malignant glioma without H3 K27M or BRAFV600 mutations. Poly adenosine diphosphate (ADP) ribose polymerases (PARPs) are proteins that help repair DNA mutations. PARP inhibitors, such as veliparib, can keep PARP from working, so tumor cells can't repair themselves, and…
ClinicalTrials.gov Identifier
NCT00898365
Principal Investigator
Anne–Marie Langevin MD
AREN03B2: Renal Tumors Classification, Biology and Banking Study
This research trial studies kidney tumors in younger patients. Collecting and storing samples of tumor tissue, blood, and urine from patients with cancer to study in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer.
ClinicalTrials.gov Identifier
NCT00772200
Principal Investigator
Anne–Marie Langevin MD
ALTE07C1, Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer
This research trial studies neuropsychological (learning, remembering or thinking) and behavioral outcomes in children and adolescents with cancer by collecting information over time from a series of tests.
ClinicalTrials.gov Identifier
NCT01790152
Principal Investigator
Anne–Marie Langevin MD
ALTE11C2, Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy
This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory from patients receiving dexrazoxane hydrochloride may help doctors learn more about the effects of dexrazoxane hydrochloride on cells. It may also help doctors understand how well patients respond to…
ClinicalTrials.gov Identifier
NCT01503086
Principal Investigator
Anne–Marie Langevin MD
ACCL10P1: Computerized Cognitive Training for Pediatric Brain Tumor Patients: A Pilot Study
This randomized clinical trial studies how well an adaptive computerized cognitive training program works compared to a non-adaptive computerized cognitive training program in treating younger patients with brain tumor who underwent radiation therapy. Providing a computer training program may improve the well-being and quality of life of patients with cognitive (physical and mental) function…
Type of Cancer
Acute Lymphoblasic Leukemia
ClinicalTrials.gov Identifier
NCT03204916
Principal Investigator
Anne–Marie Langevin MD
ACCL16N1CD, Documentation and Delivery of Guideline-Consistent Treatment in Adolescent and Young Adult (AYA) Acute Lymphoblastic Leukemia (ALL)
This study investigates cancer care delivery in adolescent and young adult patients with acute lymphoblastic leukemia. Surveying institutions, evaluating delivery of care at the patient level and seeking input from healthcare providers may help doctors increase rates of adherence to National Comprehensive Cancer Network (NCCN) treatment guidelines. It may also improve care for adolescent and…
Type of Cancer
Germ Cell Tumors of the CNS
ClinicalTrials.gov Identifier
NCT02582697
Principal Investigator
Anne–Marie Langevin MD
AGCT1532: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumours (CTMS# 18-0123)
The purpose of this study is to determine whether accelerated BEP chemotherapy is more effective than standard BEP chemotherapy in males with intermediate and poor-risk metastatic germ cell tumours.
Type of Cancer
Acute Lymphoblasic Leukemia
ClinicalTrials.gov Identifier
NCT03007147
Principal Investigator
Anne–Marie Langevin MD
AALL1631, International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones. CTMS#: 18-0142
This randomized phase III trial studies how well imatinib mesylate and combination chemotherapy work in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, work in different ways to stop the growth of cancer…
Type of Cancer
Renal Cell Carcinoma
ClinicalTrials.gov Identifier
NCT03595124
Principal Investigator
Anne–Marie Langevin MD
AREN1721: A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
This phase II trial studies how well axitinib and nivolumab work in treating patients with TFE/translocation renal cell carcinoma that cannot be removed by surgery (unresectable) or has spread to other places in the body (metastatic). Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may…
Type of Cancer
Lymphoma, Lymphoid Leukemia
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Anne–Marie Langevin MD
AALL1731: A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblast
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Anne–Marie Langevin MD
AALL1732, A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy (CTMS# 19-0169)
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Anne–Marie Langevin MD
Phase 1b/2 Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia (CTMS# 21-0097)
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Anne–Marie Langevin MD
ACNS2021: A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor (CTMS# 21-0140)
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Anne–Marie Langevin MD
Prospective Cohort Study to Evaluate Immunologic Response Following COVID-19 Vaccination in Children, Adolescents and Young Adults with Cancer (CTMS# 22-0066)
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Anne–Marie Langevin MD
A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG) (CTMS# 22-0089)
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Anne–Marie Langevin MD
APAL2020SC, Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias (CTMS# 22-0112)
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Anne–Marie Langevin MD
ACCL2031, A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine (IND# 149832) for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors (CTMS# 22-0131)
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Anne–Marie Langevin MD
AOST2032: A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma (CTMS# 23-0054)